Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000
Quantum BioPharma (NASDAQ: QNTM) has expanded its cryptocurrency investment by purchasing an additional USD $1 million worth of Bitcoin and other cryptocurrencies, bringing its total digital asset investment to USD $4.5 million. The purchase, approved by the Board of Directors, is part of the company's strategic initiative to hedge against the Canadian dollar and generate returns for shareholders. The company has established infrastructure to accept cryptocurrency-based financing and execute other transactions, with all digital assets being held by a compliant custodian. Quantum BioPharma maintains flexibility to adjust its cryptocurrency holdings based on market conditions, while ensuring compliance with financial and audit regulations.
Quantum BioPharma (NASDAQ: QNTM) ha ampliato il suo investimento in criptovalute acquistando ulteriori 1 milione di USD in Bitcoin e altre criptovalute, portando il totale degli investimenti in asset digitali a 4,5 milioni di USD. L'acquisto, approvato dal Consiglio di Amministrazione, fa parte dell'iniziativa strategica dell'azienda per coprirsi dal rischio sul dollaro canadese e generare ritorni per gli azionisti. La società ha creato un'infrastruttura per accettare finanziamenti in criptovalute ed eseguire altre transazioni, con tutti gli asset digitali custoditi da un depositario conforme alle normative. Quantum BioPharma mantiene la flessibilità di adeguare le proprie partecipazioni in criptovalute in base alle condizioni di mercato, garantendo al contempo la conformità alle normative finanziarie e di revisione.
Quantum BioPharma (NASDAQ: QNTM) ha ampliado su inversión en criptomonedas al adquirir un adicional de 1 millón de USD en Bitcoin y otras criptomonedas, elevando su inversión total en activos digitales a 4,5 millones de USD. La compra, aprobada por la Junta Directiva, forma parte de la iniciativa estratégica de la empresa para cubrirse contra el dólar canadiense y generar rendimientos para los accionistas. La compañía ha establecido una infraestructura para aceptar financiamiento basado en criptomonedas y realizar otras transacciones, con todos los activos digitales custodiados por un custodio que cumple con la normativa. Quantum BioPharma mantiene la flexibilidad de ajustar sus tenencias en criptomonedas según las condiciones del mercado, asegurando al mismo tiempo el cumplimiento de las regulaciones financieras y de auditoría.
Quantum BioPharma (NASDAQ: QNTM)는 비트코인 및 기타 암호화폐를 추가로 100만 달러 매입하여 디지털 자산 투자 총액을 450만 달러로 확대했습니다. 이 구매는 이사회 승인을 받았으며, 캐나다 달러에 대한 헤지 및 주주 수익 창출을 위한 회사의 전략적 이니셔티브의 일환입니다. 회사는 암호화폐 기반 자금 조달 및 기타 거래를 실행할 수 있는 인프라를 구축했으며, 모든 디지털 자산은 규정을 준수하는 수탁자가 보관합니다. Quantum BioPharma는 시장 상황에 따라 암호화폐 보유량을 유연하게 조정하면서 금융 및 감사 규정을 준수합니다.
Quantum BioPharma (NASDAQ : QNTM) a étendu son investissement en cryptomonnaies en achetant pour 1 million de dollars US supplémentaires en Bitcoin et autres cryptomonnaies, portant ainsi son investissement total en actifs numériques à 4,5 millions de dollars US. Cet achat, approuvé par le conseil d'administration, s'inscrit dans le cadre de l'initiative stratégique de l'entreprise visant à se couvrir contre le dollar canadien et à générer des rendements pour les actionnaires. La société a mis en place une infrastructure pour accepter des financements basés sur les cryptomonnaies et réaliser d'autres transactions, tous les actifs numériques étant détenus par un dépositaire conforme. Quantum BioPharma conserve la flexibilité d'ajuster ses avoirs en cryptomonnaies en fonction des conditions du marché, tout en garantissant le respect des réglementations financières et d'audit.
Quantum BioPharma (NASDAQ: QNTM) hat seine Investitionen in Kryptowährungen erweitert, indem es weitere Kryptowährungen im Wert von 1 Million USD in Bitcoin und anderen digitalen Währungen gekauft hat, wodurch sich die Gesamtinvestition in digitale Vermögenswerte auf 4,5 Millionen USD erhöht. Der Kauf, der vom Vorstand genehmigt wurde, ist Teil der strategischen Initiative des Unternehmens, sich gegen den kanadischen Dollar abzusichern und Renditen für die Aktionäre zu erzielen. Das Unternehmen hat eine Infrastruktur eingerichtet, um kryptowährungsbasierte Finanzierungen zu akzeptieren und andere Transaktionen durchzuführen, wobei alle digitalen Vermögenswerte von einem konformen Verwahrer gehalten werden. Quantum BioPharma behält die Flexibilität, seine Kryptowährungsbestände an die Marktbedingungen anzupassen und gewährleistet dabei die Einhaltung von Finanz- und Prüfungsanforderungen.
- Investment in cryptocurrencies provides potential hedge against Canadian dollar depreciation
- Additional revenue potential through cryptocurrency staking
- Flexibility to accept financing and conduct transactions in cryptocurrencies
- Strong compliance measures with regulated custodian services
- Exposure to highly volatile cryptocurrency market risks
- Significant capital allocation ($4.5M) to non-core business assets
- Potential regulatory risks associated with cryptocurrency holdings
TORONTO, May 19, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased an additional USD
This move reflects the company's belief in the potential of Bitcoin (BTC) and other currencies to provide a return on investment for shareholders and to provide some hedge against the Canadian dollar. The company is now set up to receive financing in cryptocurrencies as well as executing other types of transactions in cryptocurrencies.
The company is holding all its cryptocurrency with a fully compliant custodian. The company emphasizes that all transactions are and will be fully compliant with all relevant financial and audit regulations, ensuring a secure and legal process.
The Company will continue to monitor market conditions and may increase or decrease its holdings of Bitcoin (BTC) or other cryptocurrencies as it deems appropriate.
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), led by industry veterans. Quantum BioPharma retains ownership of
For more information on Quantum BioPharma, please visit www.quantumbiopharma.com.
Forward-Looking Information
Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include statements related to such.
Forward-looking information in this press release are based on certain assumptions and expected future events.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward- looking information, except as required by applicable law.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com
FAQ
How much has Quantum BioPharma (QNTM) invested in cryptocurrencies as of May 2025?
What is the purpose of QNTM's cryptocurrency investment strategy?
How does Quantum BioPharma (QNTM) store its cryptocurrency holdings?
Will Quantum BioPharma (QNTM) make additional cryptocurrency purchases in the future?
